Olema Pharmaceuticals, Inc. 8-K

What Happened
Olema Pharmaceuticals (OLMA) announced preliminary clinical results from its Phase 1 study of OP-3136, a potent KAT6 (lysine acetyltransferase 6) inhibitor, in an 8-K filed May 21, 2026. Data (cutoff March 2, 2026) come from Part 1A dose‑escalation where OP-3136 was given orally once daily in 28‑day cycles across 2–45 mg dose levels. The company will present the data in a poster at the ASCO Annual Meeting on May 30, 2026.

Key Details

• 32 heavily pretreated patients enrolled in the Part 1A cohort (ER+/HER2- advanced breast cancer, mCRPC, and mNSCLC); data cutoff March 2, 2026.
• Safety: no dose‑limiting toxicities (DLTs) observed up to 45 mg/day; most treatment‑related adverse events (TRAEs) were grade 1–2; no grade 4–5 TRAEs and no TRAE‑related discontinuations.
• Common TRAEs: dysgeusia (81% any grade; 56% grade 1, 25% grade 2), anemia (38% any grade; 6% grade 3), neutropenia (34% any grade; 28% grade 3).
• Efficacy/PD: among 19 response‑evaluable patients, tumor shrinkage in 13; 3 partial responses (2 confirmed, 1 unconfirmed); longest on treatment = 62 weeks; 11 patients remain on therapy (9 ABC, 2 mCRPC). OP-3136 showed rapid, sustained reduction of histone H3 lysine 23 (on‑target KAT6 engagement).
• Pharmacokinetics: dose‑proportional plasma exposure across doses; steady‑state concentrations at ≥6 mg exceeded preclinical efficacy targets.

Why It Matters
These early Phase 1 results indicate OP-3136 has a manageable safety profile at doses up to 45 mg/day, evidence of on‑target biological activity, and signs of anti‑tumor activity in heavily pretreated patients. For investors, the data support continued clinical development (including dose expansion) and upcoming ASCO disclosure; however, the filing includes standard forward‑looking statements and directs readers to the company’s 10‑Q risk factors for uncertainties.